Results 121 to 130 of about 14,172 (227)

Population pharmacokinetics and pharmacokinetic-pharmacodyamic modeling of antitubercular drugs [PDF]

, 2013
Includes abstract.Includes bibliographical references.The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in 78 patients with tuberculosis were described using non-linear mixed effects modeling.
Chigutsa, Emmanuel
core  

Quantitative ¹H Nuclear Magnetic Resonance Assay for the Rapid Detection of Pyrazinamide Resistance in Mycobacterium tuberculosis from Sputum Samples. [PDF]

J Clin Microbiol, 2023
Lopez JM, Zimic M, Vallejos K, Sevilla D, Quispe-Carbajal M, Roncal E, Rodríguez J, Rodríguez J, Antiparra R, Arteaga H, Gilman RH, Maruenda H, Sheen P.   +12 more
europepmc   +1 more source

Detection of Mutations in pncA in Mycobacterium tuberculosis Clinical Isolates from Nepal in Association with Pyrazinamide Resistance. [PDF]

Curr Issues Mol Biol, 2022
Shrestha D, Maharjan B, Thapa J, Akapelwa ML, Bwalya P, Chizimu JY, Nakajima C, Suzuki Y.   +7 more
europepmc   +1 more source

The epidemiology and gene mutation characteristics of pyrazinamide-resistant Mycobacterium tuberculosis clinical isolates in Southern China

Emerging Microbes and Infections
This study investigates the epidemic trend of pyrazinamide (PZA)-resistant tuberculosis in Southern China over 11 years (2012–2022) and evaluates the mutation characteristics of PZA resistance-related genes (pncA, rpsA, and panD) in clinical ...
Nan Wang, Fanrong Meng, Li Deng, Ling Wu, Yu Yang, Hua Li, Yuanjin Chen, Zeyou Wei, Bei Xie, Lan Gong, Qun Niu, Jie Lei, Junwen Gao, Bo Huang, Qi Wang, Xiaomin Lai, Zhihui Liu, Jinxing Hu   +17 more
doaj   +1 more source

Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis [PDF]

, 2000
Mycobacterium tuberculosis converts pyrazinamide to its active form by using the enzyme pyrazinamidase. This enzyme is coded for on the pncA gene, and mutations in the pncA gene result in absence of active enzyme, conferring resistance to the drug ...
Davies, A P, Gillespie, S H, Mitchison, D A, Billington, O J, McHugh, T D   +4 more
core  

Optimizing Pyrazinamide Use: A Low-Hanging Fruit in Improving Outcomes with Tuberculous Meningitis? Narrative Review

Infectious Diseases and Therapy
Tuberculous meningitis (TBM) disables more than a third of its sufferers. Recent research has focused on optimizing the antitubercular regimen, mainly by increasing the dosage of rifampicin. However, pyrazinamide, with higher penetration into the central
Bella Devaleenal Daniel, Leeberk Raja Inbaraj, Shanmugapriya Kumaravadivelu, Kathirvel Subramanian, Balaji Ramraj, Abi Manesh   +5 more
doaj   +1 more source

Performance of Wayne assay for detection of pyrazinamide resistance in Mycobacterium tuberculosis: a meta-analysis study. [PDF]

New Microbes New Infect, 2021
Nasiri MJ, Fardsanei F, Arshadi M, Deihim B, Khalili F, Dadashi M, Goudarzi M, Mirsaeidi M.   +7 more
europepmc   +1 more source

Pyrazinamide Resistance and pncA Gene Mutations in Mycobacterium tuberculosis

, 2008
Pontus Juréen, Jim Werngren, Juan-Carlos Toro, Sven Hoffner   +3 more
openalex   +2 more sources

Elucidating pyrazinamide resistance in Mycobacterium tuberculosis by molecular docking. [PDF]

, 2011
Pyrazinamide (PZA) - an important drug in the anti-tuberculosis therapy, activated by an enzyme Pyrazinamidase (PZase). The basis of PZA resistance in Mycobacterium tuberculosis (Mtb) is owing to mutation in pncA gene coding for PZase. The identification
Sudha, S, Selvakumar, N, Unissa, A N
core  

Bioinformatic analysis of Mycobacterium tuberculosis whole genome data [PDF]

Tuberculosis (TB) caused by bacteria of the Mycobacterium- tuberculosis complex (MTBC) is the second major cause of death from an infectious disease worldwide.
Coll I Cerezo, F
core   +1 more source